Patents by Inventor R. Michael Molloy
R. Michael Molloy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6111067Abstract: A82846-related glycopeptide compounds are prepared by treating an antibiotic selected from A82846 components A, B and C with trifluoroacetic acid to remove 1) the .alpha.-L-O-4-epi-vancosaminyl group attached to the disaccharide; 2) the (.alpha.-L-O-4-epi-vancosaminyl-.beta.-O-glucosyl) disaccharide group or 3) both the disaccharide group and the .alpha.-L-O-4-epi-vancosaminyl group attached to the peptide core from these antibiotics. The compounds have antibacterial activity, especially against Gram-positive microorganisms.Type: GrantFiled: December 21, 1993Date of Patent: August 29, 2000Assignee: Eli Lilly and CompanyInventors: Manuel Debono, R. Michael Molloy, Ramakrishnan Nagarajan, Amelia A. Schabel
-
Patent number: 5912226Abstract: Two new groups of A-21978C cyclic peptides, anhydro- and isomer-A21978C peptide derivatives, have antibacterial activity and are useful as intermediates. The two groups are prepared via transpeptidation of the parent cyclic peptides. Pharmaceutical formulations containing the new peptides as active ingredients and methods of treating infections caused by susceptible Gram-positive bacteria with the formulations are also provided.The invention also provides an antibacterial composition containing the new drug substance LY 146032 in substantially pure form.Type: GrantFiled: December 16, 1991Date of Patent: June 15, 1999Assignee: Eli Lilly and CompanyInventors: Patrick J. Baker, Manuel Debono, Khadiga Z. Farid, R. Michael Molloy
-
Patent number: 5534420Abstract: New glycopeptides prepared by biotransformation of a vancomycin-type antibiotic by an Acinomadura citrea culture (NRRL 18382), which are useful intermediates, and methods of preparing the biotransformed intermediates by adding a vancomycin-type glycopeptide to a growing culture of Actinomadura citrea NRRL 18382 and continuing fermentation under submerged aerobic conditions, are provided.Type: GrantFiled: May 18, 1995Date of Patent: July 9, 1996Assignee: Eli Lilly and CompanyInventors: Manuel Debono, Robert M. Logan, Gary G. Marconi, R. Michael Molloy, Milton J. Zmijewski, Jr.
-
Patent number: 5451403Abstract: Fermentation product A87689 is produced by a strain of Amycolatopsis mediterranei selected from NRRL 18815 and NRRL 18851, or an A87689-producing mutant thereof. A87689, its C.sub.1-6 -alkyl ether and C.sub.1-6 -alkanoyl ester derivatives and pharmaceutically acceptable salts thereof are phospholipase A.sub.2 inhibitors that are useful as antiinflammatory agents. Fermentation products known as BU-3889V, its components and pharmaceutically acceptable salts thereof, are phospholipase A.sub.2 inhibitors that are also useful as antiinflammatory agents.Type: GrantFiled: April 28, 1994Date of Patent: September 19, 1995Assignee: Eli Lilly and CompanyInventors: Dennis R. Berry, Anne H. Dantzig, Manuel Debono, Robert Hamill, R. Michael Molloy, Raymond C. Yao
-
Patent number: 5350579Abstract: Fermentation product A87689 is produced by a strain of Amycolatopsis mediterranei selected from NRRL 18815 and NRRL 18851, or an A87689-producing mutant thereof. A87689, its C.sub.1-6 -alkyl ether and C.sub.1-6 -alkanoyl ester derivatives and pharmaceutically acceptable salts thereof are phospholipase A.sub.2 inhibitors that are useful as antiinflammatory agents. Fermentation products known as BU-3889V, its components and pharmaceutically acceptable salts thereof, are phospholipase A.sub.2 inhibitors that are also useful as antiinflammatory agents.Type: GrantFiled: August 9, 1993Date of Patent: September 27, 1994Assignee: Eli Lilly and CompanyInventors: Dennis R. Berry, Anne H. Dantzig, Manuel Debono, Robert Hamill, R. Michael Molloy, Raymond C. Yao
-
Patent number: 5278064Abstract: Fermentation product A87689 is produced by a strain of Amycolatopsis mediterranei selected from NRRL 18815 and NRRL 18851, or an A87689-producing mutant thereof. A87689, its C.sub.1-6 -alkyl ether and C.sub.1-6 -alkanoyl ester derivatives and pharmaceutically acceptable salts thereof are phospholipase A.sub.2 inhibitors that are useful as antiinflammatory agents. Fermentation products known as BU-3889V, its components and pharmaceutically acceptable salts thereof, are phospholipase A.sub.2 inhibitors that are also useful as antiinflammatory agents.Type: GrantFiled: May 4, 1992Date of Patent: January 11, 1994Assignee: Eli Lilly and CompanyInventors: Dennis R. Berry, Anne H. Dantzig, Manuel Debono, Robert Hamill, R. Michael Molloy, Raymond C. Yao
-
Patent number: 4639433Abstract: Novel glycopeptide derivatives of formula 1 and methods for their preparation from the glycopeptide antibiotics vancomycin, A51568A, A51568B, M43A and M43D, are provided. The new glycopeptide derivatives are useful antibacterial agents.Type: GrantFiled: August 14, 1985Date of Patent: January 27, 1987Assignee: Eli Lilly and CompanyInventors: Ann H. Hunt, R. Michael Molloy, Ramakrishnan Nagarajan, Amelia A. Schabel
-
Patent number: 4504467Abstract: Method of preparing compounds of formula 1: ##STR1## by oxidative deamination of a glycopeptide antibiotic of formula 2: ##STR2## the antibiotic being selected from A35512 factors A, B, C, E and H, A35512B pseudoaglycone, actaplanin factors A, B.sub.1, B.sub.2, B.sub.3, C.sub.1a, C.sub.2a, C.sub.3, D.sub.1, D.sub.2, E.sub.1, G, K, L, M, N and O, actaplanin pseudoaglycone, A41030 factors A, B, C, D, E, F and G, A47934, ristocetin A and ristocetin A pseudoaglycone, novel compounds and compositions and methods of increasing feed-utilization efficiency in animals are provided.Type: GrantFiled: October 21, 1983Date of Patent: March 12, 1985Assignee: Eli Lilly and CompanyInventors: R. Michael Molloy, Manuel Debono
-
Patent number: 4228293Abstract: Iodo-A-23187 derivatives, prepared by reaction of antibiotic A-23187 with iodine monochloride, and salts thereof, which are (1) useful biochemical tools for the study of transport of ions in cellular systems and (2) useful chemical tools for removal of recovery of ions.Type: GrantFiled: October 11, 1978Date of Patent: October 14, 1980Assignee: Eli Lilly and CompanyInventors: R. Michael Molloy, Manuel Debono
-
Patent number: 4227002Abstract: Halo-A-23187 derivatives, prepared by reaction of antibiotic A-23187 with an N-halo-type halogenating agent, and salts thereof, which are (1) useful biochemical tools for the study of transport of ions in cellular systems, (2) useful chemical tools for removal and recovery of ions, and (3) potential cardiotonic agents.Type: GrantFiled: October 11, 1978Date of Patent: October 7, 1980Assignee: Eli Lilly and CompanyInventors: Donner F. Babcock, Charles M. Deber, Manuel Debono, R. Michael Molloy, Douglas R. Pfeiffer
-
Patent number: 4227003Abstract: Bromo-A-23187 derivatives, prepared by reaction of antibiotic A-23187 with pyridinium hydrobromide perbromide and salts thereof, which are (1) useful biochemical tools for the study of transport of ions in cellular systems, and (2) useful chemical tools for removal and recovery of ions.Type: GrantFiled: October 11, 1978Date of Patent: October 7, 1980Assignee: Eli Lilly and CompanyInventors: Manuel Debono, R. Michael Molloy
-
Patent number: RE39071Abstract: Two new groups of A-21978C cyclic peptides, anhydro- and isomer-A21978C peptide derivatives, have antibacterial activity and are useful as intermediates. The two groups are prepared via transpeptidation of the parent cyclic peptides. Pharmaceutical formulations containing the new peptides as active ingredients and methods of treating infections caused by susceptible Gram-positive bacteria with the formulations are also provided. The invention also provides an antibacterial composition containing the new drug substance LY 146032 in substantially pure form.Type: GrantFiled: April 11, 2000Date of Patent: April 18, 2006Assignee: Eli Lilly and CompanyInventors: Patrick J. Baker, Manuel Debono, Khadiga Z. Farid, R. Michael Molloy